Terms: = Endocrine gland cancer AND MSN, P26038, 4478, ENSG00000147065
34 results:
1. CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer.
Slapak EJ; El Mandili M; Ten Brink MS; Kros A; Bijlsma MF; Spek CA
Cancer Lett; 2024 May; 590():216845. PubMed ID: 38589004
[TBL] [Abstract] [Full Text] [Related]
2. The inhibition of pancreatic cancer progression by K-Ras-overexpressing mesenchymal stem cell-derived secretomes.
Huo Q; Li K; Sun X; Zhuang A; Minami K; Tamari K; Ogawa K; Fishel ML; Li BY; Yokota H
Sci Rep; 2023 Sep; 13(1):15036. PubMed ID: 37699930
[TBL] [Abstract] [Full Text] [Related]
3. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic cancer.
Slapak EJ; El Mandili M; Brink MST; Kros A; Bijlsma MF; Spek CA
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445886
[TBL] [Abstract] [Full Text] [Related]
4. Nanoparticles loaded with circ_0086375 for suppressing the tumorigenesis of pancreatic cancer by targeting the miR-646/SLC4A4 axis.
Wang Y; Zhang M; Zhang L; Zhou M; Wang E
Clin Exp Metastasis; 2023 Feb; 40(1):53-67. PubMed ID: 36479657
[TBL] [Abstract] [Full Text] [Related]
5. Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary cancer Variants in Patients with High-Grade Serous Carcinoma.
Goebel EA; Kerkhof J; Dzyubak O; McLachlin CM; McGee J; Sadikovic B
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011309
[TBL] [Abstract] [Full Text] [Related]
6. Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer.
Tarannum M; Holtzman K; Dréau D; Mukherjee P; Vivero-Escoto JL
J Control Release; 2022 Jul; 347():425-434. PubMed ID: 35569588
[TBL] [Abstract] [Full Text] [Related]
7. A Space-Time Conversion Vehicle for Programmed Multi-Drugs Delivery into Pancreatic Tumor to Overcome Matrix and Reflux Barriers.
Huo T; Zhang X; Qian M; Nie H; Liang D; Lin C; Yang Y; Guo W; Lächelt U; Huang R
Adv Sci (Weinh); 2022 Jul; 9(20):e2200608. PubMed ID: 35508899
[TBL] [Abstract] [Full Text] [Related]
8. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.
Wang X; Xiong T; Cui M; Li N; Li Q; Zhu L; Duan S; Wang Y; Guo Y
J Nanobiotechnology; 2021 Dec; 19(1):444. PubMed ID: 34949180
[TBL] [Abstract] [Full Text] [Related]
9. Hydrolytic surface erosion of mesoporous silica nanoparticles for efficient intracellular delivery of cytochrome c.
Choi E; Lim DK; Kim S
J Colloid Interface Sci; 2020 Feb; 560():416-425. PubMed ID: 31679782
[TBL] [Abstract] [Full Text] [Related]
10. Development of Mesoporous Silica Nanoparticles of Tunable Pore Diameter for Superior Gemcitabine Drug Delivery in Pancreatic cancer Cells.
Saini K; Prabhuraj RS; Bandyopadhyaya R
J Nanosci Nanotechnol; 2020 May; 20(5):3084-3096. PubMed ID: 31635652
[TBL] [Abstract] [Full Text] [Related]
11. Destruction of tumor mass by gadolinium-loaded nanoparticles irradiated with monochromatic X-rays: Implications for the Auger therapy.
Matsumoto K; Saitoh H; Doan TLH; Shiro A; Nakai K; Komatsu A; Tsujimoto M; Yasuda R; Kawachi T; Tajima T; Tamanoi F
Sci Rep; 2019 Sep; 9(1):13275. PubMed ID: 31570738
[TBL] [Abstract] [Full Text] [Related]
12. Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.
Wang P; Magdolen V; Seidl C; Dorn J; Drecoll E; Kotzsch M; Yang F; Schmitt M; Schilling O; Rockstroh A; Clements JA; Loessner D
Br J Cancer; 2018 Oct; 119(7):1-9. PubMed ID: 30287916
[TBL] [Abstract] [Full Text] [Related]
13. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer.
Shahin SA; Wang R; Simargi SI; Contreras A; Parra Echavarria L; Qu L; Wen W; Dellinger T; Unternaehrer J; Tamanoi F; Zink JI; Glackin CA
Nanomedicine; 2018 Jun; 14(4):1381-1394. PubMed ID: 29665439
[TBL] [Abstract] [Full Text] [Related]
14. Cellular Migration Ability Is Modulated by Extracellular Purines in Ovarian Carcinoma SKOV-3 Cells.
Martínez-Ramírez AS; Díaz-Muñoz M; Battastini AM; Campos-Contreras A; Olvera A; Bergamin L; Glaser T; Jacintho Moritz CE; Ulrich H; Vázquez-Cuevas FG
J Cell Biochem; 2017 Dec; 118(12):4468-4478. PubMed ID: 28464260
[TBL] [Abstract] [Full Text] [Related]
15. Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models.
Roberts CM; Shahin SA; Wen W; Finlay JB; Dong J; Wang R; Dellinger TH; Zink JI; Tamanoi F; Glackin CA
Nanomedicine; 2017 Apr; 13(3):965-976. PubMed ID: 27890656
[TBL] [Abstract] [Full Text] [Related]
16. A phase II single institution single arm prospective study with paclitaxel, ifosfamide and cisplatin (TIP) as first-line chemotherapy in high-risk germ cell tumor patients with more than ten years follow-up and retrospective correlation with ERCC1, Topoisomerase 1, 2A, p53 and HER-2 expression.
Ligia Cebotaru C; Zenovia Antone N; Diana Olteanu E; Bejinariu N; Buiga R; Todor N; Ioana Iancu D; Eliade Ciuleanu T; Nagy V
J BUON; 2016; 21(3):698-708. PubMed ID: 27569093
[TBL] [Abstract] [Full Text] [Related]
17. Pathways Regulating Spheroid Formation of Human Follicular Thyroid cancer Cells under Simulated Microgravity Conditions: A Genetic Approach.
Riwaldt S; Bauer J; Wehland M; Slumstrup L; Kopp S; Warnke E; Dittrich A; Magnusson NE; Pietsch J; Corydon TJ; Infanger M; Grimm D
Int J Mol Sci; 2016 Apr; 17(4):528. PubMed ID: 27070589
[TBL] [Abstract] [Full Text] [Related]
18. Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography.
Gurka MK; Pender D; Chuong P; Fouts BL; Sobelov A; McNally MW; Mezera M; Woo SY; McNally LR
J Control Release; 2016 Jun; 231():60-7. PubMed ID: 26763377
[TBL] [Abstract] [Full Text] [Related]
19. Antibody fragment-armed mesoporous silica nanoparticles for the targeted delivery of bevacizumab in ovarian cancer cells.
Zhang Y; Guo J; Zhang XL; Li DP; Zhang TT; Gao FF; Liu NF; Sheng XG
Int J Pharm; 2015 Dec; 496(2):1026-33. PubMed ID: 26541303
[TBL] [Abstract] [Full Text] [Related]
20. Pituitary macroadenomas (>3 cm) in young adulthood: Pathologic and proliferative characteristics.
Öngürü Ö; Düz B; Şimşek H; Günal A; Gönül E
Neurol Neurochir Pol; 2015; 49(4):212-6. PubMed ID: 26188936
[TBL] [Abstract] [Full Text] [Related]
[Next]
